Is BPC-157 approved by the FDA?

No. BPC-157 is not approved for human use and is sold strictly as a research chemical. The FDA has flagged it for restrictions in compounding. All use described here is for educational and research purposes only.

What is BPC-157 most studied for?

The bulk of preclinical literature focuses on soft-tissue healing (tendons, ligaments, muscle), gastrointestinal protection, and angiogenesis. Human clinical trials remain limited.

How does BPC-157 differ from TB-500?

BPC-157 primarily drives angiogenesis and local tissue repair, while TB-500 (Thymosin Beta-4) acts on actin regulation and cell migration. They are frequently studied together for complementary healing pathways.

← All peptides

Healing & Recovery

Research Chemical

BPC-157

Also known as: BPC-157, Body Protection Compound-157

A synthetic peptide fragment derived from a protein found in gastric juice, studied for its broad tissue-healing and cytoprotective effects. Popular in research for tendon, ligament, muscle, and gut repair.

Mechanism of Action

BPC-157 is thought to upregulate angiogenesis by promoting VEGFR2 expression and activating the VEGFR2-Akt-eNOS signaling pathway, increasing blood vessel formation at injury sites. It modulates growth-hormone receptor expression in tendon fibroblasts and appears to influence the nitric oxide system. Animal studies also describe protective effects on the gut-brain axis and dopaminergic, serotonergic, and GABAergic systems.

Half-life: Approximately 4-6 hours (estimated; rapidly cleared)
Administration Routes: subcutaneous, intramuscular, oral
Research Status: Research Chemical